Pipeline Integration Leaves Merck's Backbone As Cardiovascular, Infectious Disease
This article was originally published in Pharmaceutical Approvals Monthly
Merck & Co.'s new late-stage pipeline, which integrates Schering-Plough's assets, positions it as a leader in cardiovascular disease and infectious disease drug development. Other therapeutic areas in the lineup include oncology, central nervous system disorders, diabetes and vaccines, and new opportunities in women's health
You may also be interested in...
News of Pfizer's takeover of Wyeth has hardly had time to sink in and already a second mega-merger is shaking up big pharma. This time Merck is the buyer; the company announced March 9 that it proposes to acquire its cardiovascular joint venture partner Schering-Plough in a deal valued at $41.1 billion
Despite several setbacks this year, and a major competitor's withdrawal from further R&D in the field, Merck reiterated its commitment to cardiovascular R&D at its annual business review Dec. 9 and outlined an aggressive cardiovascular development program
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011